S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer

A systematic review and meta-analysis protocol

Feiyu Liu, MD, Chaoyang Wang, MD, Tao Hu, MD, Wei Wang, MD, PhD,∗

Abstract

Background: Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung cancer accounts for >75% of all lung cancer cases. Cisplatin-based concurrent chemoradiotherapy has become the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Third-generation chemotherapy agents plus cisplatin have been most commonly used in concurrent chemoradiotherapy, which is also associated with more adverse effects and acute toxicities. S-1 as an oral chemotherapeutic agent exhibits higher antitumor activity, less adverse effects, and better biological availability. Recently, studies illustrated S-1-based concurrent chemoradiotherapy also had excellent effects in the treatment of locally advanced NSCLC.

Methods: A systematic literature search will be performed through February 2018 using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Google Scholar for relevant articles published in any language. Randomized controlled trials and prospective comparative studies will be included. All meta-analyses will be performed using Review Manager software. The quality of the studies will be evaluated using the guidelines listed in the Cochrane Handboook. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements will be followed until the findings of the systematic review and meta-analysis are reported.

Results: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.

Conclusion: Our study will draw an objective conclusion of the efficacy and safety of S-1-based chemoradiotherapy in the treatment of locally advanced unresectable NSCLC and provides level I evidence for clinical decision makings.

Abbreviations: 5-FU = 5-fluorouracil, CDHP = gimeracil, CI = confidence interval, CRT = chemoradiotherapy, FT = tegafur, GRADE = Grading of Recommendations Assessment, Development and Evaluation, IASLC = International Association for the Study of Lung Cancer, NSCLC = non-small cell lung cancer, ORR = objective response rate, OS = overall survival, Oxo = oteracil, PFS = progression-free survival, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA-P = Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, RCT = randomized controlled trial, RR = relative risk, SMD = standardized mean difference.

Keywords: chemoradiotherapy, CRT, non-small cell lung cancer, NSCLC, S-1

1. Introduction

Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung cancer (NSCLC) accounts for >75% of all lung cancer cases.1,2 Approximately 30% of all lung cancer patients are diagnosed with stage III disease,3 for whom chemotherapy and radiotherapy utilized alone or combinedly are mainly nonsurgical treatment options. Previous randomized phase III study has illustrated that concurrent chemoradiotherapy (CRT) has advantages over sequential chemoradiotherapy in terms of response and survival.4 Cisplatin-based CRT has become the standard treatment for locally advanced NSCLC.5–8 Nevertheless, third-generation chemotherapy agents plus cisplatin have been most commonly used in CRT, which is also associated with more adverse effects and acute toxicities compared with sequential chemoradiotherapy.9 Therefore, exploring new CRT regimens with better tolerance and lower toxicity for patients with NSCLC are desperately needed.

S-1 is a novel oral combination drug comprising tegafur (FT), a prodrug of 5-fluorouracil (5-Fu), and 2 modulators of 5-FU metabolism, gimeracil (CDHP), and oteracil (Oxo), in a 1:0.4:1

© 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ethics and dissemination: Ethical approval and informed consent are not required, as the study will be a literature review and will not involve direct contact with patients or alterations to patient care.

Trial registration number: PROSPERO (CRD42018087982).

Competing interests: None declared.

Trial registration number: PROSPERO (CRD42018087982).

Ethics and dissemination: Ethical approval and informed consent are not required, as the study will be a literature review and will not involve direct contact with patients or alterations to patient care.

Trial registration number: PROSPERO (CRD42018087982).

Competing interests: None declared.

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97(15):e10397

Received: 8 March 2018 / Accepted: 21 March 2018
http://dx.doi.org/10.1097/MD.0000000000010397
molar ratio (FT:CDHP:Oxo). Evidence suggested that S-1 exhibits higher antitumor activity, less adverse effects, and better biological availability while compared with conventional 5-FU,[10–12] which can sensitize cancer cells to radiotherapy.[13] In recent years, S-1 as an excellent CRT drug, single use or combined with platinum, has been widely applied for advanced NSCLC and achieved good clinical outcomes.[14–20] However, the sample size of these studies was relatively small and results in weak statistical power. Therefore, we conduct a systematic review and meta-analysis related to S-1-based CRT versus non-S-1-based CRT in the treatment of advanced NSCLC to further evaluate the clinical value of S-1. Moreover, in order to minimize the heterogeneity and bias, we will select randomized controlled trials (RCTs) and prospective comparative studies. The evidence grade will be determined by using the guidelines of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. If data are sufficient, we will also conduct subgroup analyses using different histological types.

2. Objective
A systematic review and meta-analysis will be performed to assess the efficacy and safety of S-1-based CRT in the treatment of patients with locally advanced NSCLC.

3. Methods
This protocol for systematic review and meta-analysis is performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement.[21] This protocol has been registered in the PROSPERO network (registration number: CRD42018087982). The systematic review and meta-analysis will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[22]

4. Eligibility criteria
4.1. Types of participants
The included participants will be adults who were diagnosed with locally advanced NSCLC histologically or cytologically confirmed and treated with CRT. Comparisons of S-based CRT with non-S-1-based CRT in the clinical treatment were evaluated. There will be no restrictions regarding sex, race/ethnicity, education and economic status, and no restriction in publication language.

4.2. Types of studies
We propose to include studies that report comparisons between S-1-based CRT and non-S-1-based CRT in the treatment of locally advanced NSCLC. RCTs and prospective comparative studies will be used for the qualitative and quantitative synthesis of the systematic review.

4.3. Exclusion criteria
Non-peer-reviewed articles, review articles, case reports, case series, animal studies, meeting abstracts, letters to the editor, commentaries, editorials, proceedings, and other nonrelevant studies will be excluded from analysis.

4.4. Information sources
We will perform a systematic literature search through February 28, 2018 using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Google Scholar for relevant articles published in any language.

4.5. Search strategy
The relevant searching terms will match Medical Subject Heading terms, and the searches will be repeated immediately before the final analyses to identify additional studies for inclusion. An example of the PubMed search strategy is shown in Table 1.

4.6. Study records
4.6.1. Selection of studies. Two review authors (FL and CW) will independently screen titles and abstracts of all the potential studies to assess whether they meet the inclusion criteria as defined by the protocol. We will retrieve the full text of all potentially eligible studies and 2 review authors (FL and CW) will independently screen the full-text and identify studies for inclusion, and record reasons for exclusion of the ineligible studies. Any disagreement will be resolved through discussion or, if required, consultation with a third review author (TH or WW). Duplicates will be excluded and multiple reports of the same study will be integrated into one unit of interest in the review. The selection process will be recorded in sufficient detail to complete a PRISMA flow diagram and “Characteristics of excluded studies” table.[23] No language restrictions will be imposed.

4.6.2. Data extraction and management. Data will be extracted from the included studies by 3 authors (FL, CW, and TH) independently and recorded on a predesigned data collection form. We will extract the following study characteristics:

(1) Study characteristics: study design, number of study centers and locations, study setting, withdrawals, total duration of the trial, periods of data collection, follow-up duration, and blanking periods.

(2) Population characteristics: inclusion and exclusion criteria, number, mean age, age range, gender, diagnostic criteria,

| Table 1 |
|---|
| Search strategy for PubMed. |
| Query | Search term |
| #1 | “Carcinoma, Non-Small-Cell Lung”[Mesh] OR non-small cell lung carcinoma OR non-small cell lung cancer OR nonsmall cell lung carcinoma OR nonsmall cell lung cancer OR non-small cell lung carcinoma OR non-small cell lung cancer OR lung adenocarcinoma OR lung squamous carcinoma |
| #2 | S-1 OR tegafur OR FT OR gimeracil OR CDHP OR oteracil OR Oxo |
| #3 | Chemoradiotherapy OR CRT OR radiotherapy OR radiation |
| #4 | Randomized OR control OR randomly OR trial OR comparative OR prospective |
| #5 | #1 AND #2 AND #3 AND #4 |
pathological confirmation, staging of the tumor according to the IASLC (International Association for the Study of Lung Cancer) TNM classification for lung cancer.

3) Intervention characteristics: total radiation dose, fractions, chemotherapy agents dose, administration frequency, and cycles.

4) Outcomes: primary and secondary outcomes specified and collected, and time points reported.

4.6.3. Outcomes

4.6.3.1. Primary outcome. The primary outcome measure of our systematic review is overall survival (OS).

4.6.3.2. Secondary outcomes. The secondary outcomes are: objective response rate (ORR), progression-free-survival (PFS), grade 3 and 4 adverse events.

4.6.3.3. Assessment of risk of bias. Three review authors (FL, CW, and TH) will independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. Any disagreements will be resolved by discussion or by involving another review author (WW). The risk of bias will be assessed according to the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other bias. Each potential source of bias will be graded as high, low, or unclear and a quote from the study report with a justification for our judgement will be provided in the “Risk of bias” table. The risk of bias judgements across different studies for each of the domains listed will be summarized.

4.6.3.4. Data synthesis. Data from studies judged to be clinically homogenous will be pooled using Review Manager 5.3 software. Heterogeneity between studies will be assessed using the Cochran’s Q and Higgins I^2 statistic. P < .10 for the Chi^2 statistic or an I^2 > 50% will be considered as showing considerable heterogeneity, and the data will be analyzed using the random-effect model. Otherwise, the fixed-effect model will be used. The Mantel-Haenszel method will be applied for pooling of dichotomous data and results will be presented as relative risk (RR) with their 95% confidence intervals (CI). Inverse variance method will be used for pooling of continuous data and results will be presented as standardized mean difference (SMD) with their 95% CI.

4.6.3.5. Subgroup analysis. If data are sufficient, we will conduct subgroup analyses on different histological types: adenocarcinoma and squamous carcinoma. Subgroup analyses will also be performed to explore potential sources of heterogeneity.

4.6.3.6. Sensitivity analysis. A sensitivity analysis will be performed to confirm whether the pooled results are robust and credible by excluding highly biased studies.

4.6.3.7. Dealing with missing data. In the condition of missing or unclear data, study authors will be contacted at the eligibility assessment and/or data extraction stage. Secondary publications may be considered as missing data if they have the same study population.

4.6.3.8. Publication bias. Egger’s regression test will be performed to assess the publication bias of the included studies. If there is a publication bias, trim and fill analysis will be performed.

4.6.3.9. Evidence evaluation. The evidence grade will be determined by using the guidelines of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system, and using 4 levels—high quality, moderate quality, low quality, and very low quality.

5. Discussion

S-1 is a promising chemotherapy agent with good efficacy and acceptable tolerability in various solid tumors, such as advanced gastric cancer,[26] colorectal cancer,[10] esophageal cancer,[27] NSCLC,[12] pancreatic cancer,[11] and head and neck cancer.[128]

As mentioned above, S-1 has also exhibited excellent effects as a CRT regimen for locally advanced NSCLC. This protocol presents the methodology of a systematic review for assessing the efficacy and safety of S-1 combined with radiotherapy in the treatment of advanced unresectable NSCLC. We will comprehensively search, screen, assess, and extract valuable data from several databases as previously mentioned, and report this review results according to the PRISMA guidelines. To our knowledge, this will be the first systematic review and meta-analysis comparing the efficacy and safety of S-1-based CRT with non-S-1-based CRT in the treatment of locally advanced NSCLC.

Authors’ contributors

FL, CW, and WW conceived and designed this study. FL and CW drafted the protocol. FL, CW and TH will conduct the search, data screening and extraction. FL, CW, TH and WW have critically reviewed the manuscript and approved it for publication.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30.
[2] Hong QY, Wu GM, Qian GS, et al. Prevention and management of lung cancer in China. Cancer 2015;121(suppl 17):3080–8.
[3] van Meerbeeck JP. Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung cancer (Amsterdam, Netherlands) 2001;34(suppl 2):S95–107.
[4] Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692–9.
[5] Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCG0007. J Clin Oncol 2010;28:3299–306.
[6] Kuyama S, Hotta K, Tabata M, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. Lung Cancer 2008;54:477–82.
[7] Chikamori K, Kishino D, Takigawa N, et al. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2009;65:74–9.
[8] O’Rourke N, Roque IFM, Farre Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;6:CD002140.
[9] Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90.
[10] Sadahiro S, Suzuki T, Tanaka A, et al. Phase III study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma. Oncology 2011;81:306–11.
[11] Sudo K, Yamaguchi T, Ishihara T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;80:119–25.

[12] Kawahara M. Efficacy of S-1 in non-small cell lung cancer. Expert Opin Pharmacother 2014;15:1927–42.

[13] Harada K, Kawaguchi S, Supriatno OT, et al. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004;40:713–9.

[14] Taira T, Yoh K, Nagase S, et al. Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2018;81:565–72.

[15] Aoe K, Takigawa N, Hotta K, et al. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer (Oxford, England: 1990) 2014;50:2783–90.

[16] Nogami N, Takigawa N, Hotta K, et al. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer (Amsterdam, Netherlands) 2015;87:141–7.

[17] Feng J, Xu J, Wang X, et al. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: a multicentre randomized controlled trial. Medicine (Baltimore) 2016;95:e4557.

[18] Shukuya T, Takahashi T, Harada H, et al. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. Anticancer Res 2012;32:673–80.

[19] Wang T, Zhang SF, Quo MQ, et al. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Cancer Radiother 2016;20:181–6.

[20] Yao L, Xu S, Xu J, et al. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial. Radiother Oncol (London, England) 2015;10:10.

[21] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7247.

[22] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

[23] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.

[24] Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 2012;3:161–76.

[25] Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9:e99632.

[26] Li DH, Pan ZK, Ye F, et al. S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials. Tumour Biol 2014;35:8201–8.

[27] Iwase H, Shimada M, Tsuruki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology 2013;84:342–9.

[28] Tahara M, Minami H, Kawashima M, et al. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Sci 2011;102:419–24.